J&J's tapentadol improves GI tolerability
Results from two Phase III clinical studies of US health care major Johnson & Johnson's tapentadol immediate-release tablets suggest significantly improved gastrointestinal tolerability as well as safety profile versus oxycodone HCl IR. The data were presented at the European League Against Rheumatism annual meeting in Paris, France.
The agent is a novel, centrally-acting analgesic that has two mechanisms of action, combining mu-opioid receptor agonism and noradrenaline reuptake inhibition in a single molecule. A study in patients with end-stage joint disease showed that treatment with 50mg or 75mg tapentadol IR resulted in significantly higher pain relief compared to placebo (p<0.001) when assessed over five days of treatment. In addition, patients treated with tapentadol experienced significantly fewer GI side effects compared to those given 10mg of oxycodone IR.
The 50mg and 75mg tapentadol IR treatment groups showed similar efficacy to that seen in patients treated with 10mg of oxycodone HCl IR.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze